April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Non-Infectious Endophthalmitis (NIE) After Intravitreal Ranibizumab
Author Affiliations & Notes
  • Q. Ghadiali
    Robert Wood Johnson Medical School, New Brunswick, New Jersey
  • M. A. William
    Robert Wood Johnson Medical School, New Brunswick, New Jersey
  • H. F. Fine
    Retina Vitreous Center, UMDNJ, New Brunswick, New Jersey
  • J. L. Prenner
    Retina Vitreous Center, UMDNJ, New Brunswick, New Jersey
  • Footnotes
    Commercial Relationships  Q. Ghadiali, None; M.A. William, None; H.F. Fine, Auris Surgical Robotics, I; Genentech, C; Allergan, C; Eyetech, C; Auris Surgical Robotics, C; Auris Surgical Robotics, P; J.L. Prenner, Neovista, E; Ophthotech, E; OPKO, E; Alcon Laboratories, Inc., C; Allergan, Inc., C; Eyetech (OSI), C; Neovista, C; Ophthotech, C; OPKO, C; OPKO, P.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 6055. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Q. Ghadiali, M. A. William, H. F. Fine, J. L. Prenner; Non-Infectious Endophthalmitis (NIE) After Intravitreal Ranibizumab. Invest. Ophthalmol. Vis. Sci. 2010;51(13):6055.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To report multiple cases of NIE after intravitreal injection of ranibizumab.

Methods: : Retrospective case series.

Results: : Three cases of NIE were discovered after injection of intravitreal ranibizumab over a one year time period. Eyes presented with marked anterior chamber cellular reaction, corneal endotheliitis, but only a mild pseudogranulomatous vitritis. All eyes had been previously treated with ranibizumab (average 10.6). Patients presented quickly after injection (4.3 days) with reports of visual loss and mild pain. Topical steroids were utilized as monotherapy and all eyes returned to baseline visual acuity by day 30.

Conclusions: : NIE has been well documented after intravitreal bevacizumab. This is the first report of NIE after ranibizumab. The predominantly anterior reaction and response to topical therapy are typical of NIE.

Keywords: endophthalmitis • age-related macular degeneration • injection 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.